The top anchor investors in the IPO included Nippon India Mutual Fund, Kotak MF, Aditya Birla Sun Life MF, Quant MF and Carnelian Bharat Amritkaal Fund, according to a circular uploaded on BSE’s website.
The company has allotted 57.57 lakh equity shares to 16 funds at ₹441 apiece, which is also the upper end of the price band. This aggregates the transaction size to ₹254 crore, the circular showed.
Also Read: Will Enviro Infra Engineers see healthy listing gains on Friday?
The ₹846-crore initial share sale will open for public subscription on November 29 and conclude on December 3. The shares will be available in the price range of ₹420 to ₹441 apiece.
The Kolkata-headquartered company’s IPO consists of an Offer for Sale (OFS) of 19,189,330 equity shares worth ₹846.25 crore, at the upper end of the price band, by promoters and investor shareholders, with no fresh issue component.
Under the OFS, promoters Somnath Chatterjee, Ritu Mittal, and Satish Kumar Verma; and investors OrbiMed Asia II Mauritius Ltd, Munna Lal Kejriwal and Santosh Kumar Kejriwal will offload shares. Since the issue is completely an OFS, the company will not receive any proceeds and all the funds will go to the selling shareholders.
Explaining the reason for going public, the company said it is aimed at achieving the benefit of listing equity shares on the stock exchanges and carrying out OFS for the selling shareholders. At the upper end of the price band, the company’s market capitalisation stands at around ₹2,300 crore.
Also Read: Suraksha Diagnostic IPO opens tomorrow: Here’s what GMP indicates
Suraksha Diagnostic offers a one-stop integrated solution for pathology and radiology testing and medical consultation services to its customers through its extensive operational network, consisting of a flagship central reference laboratory, 8 satellite laboratories and 194 customer touchpoints which include 48 diagnostic centres, and 146 sample collection centres (primarily franchised), across West Bengal, Bihar, Assam and Meghalaya as of March 31, 2024.
During fiscal 2024, it conducted about 5.98 million tests serving approximately 1.14 million patients. Half of the issue size has been reserved for qualified institutional buyers (QIBs), 35% for retail investors and the remaining 10 per cent for non-institutional investors.
ICICI Securities Ltd, Nuvama Wealth Management Ltd and SBI Capital Markets Ltd are the book-running lead managers to the issue. The equity shares are expected to be listed on BSE and NSE on December 6.
Also Read: NTPC Green Energy share price lists at 3% premium over IPO price
